Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06690359 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

IM19 CAR-T Cell Therapy for IgA Nephropathy Patients and Membranous Nephropathy Patients

StatusNot Yet Recruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 26, 2024 (before its estimated August 4, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Start date: Nov 4, 2024 to Dec 13, 2024v3
  2. Eligibility criteria shortened, about 17 wordsv2 See this version in full on ClinicalTrials.gov ↗
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
IM19 CAR-T cell therapy for IgA nephropathy patients with urinary protein and renal dysfunction, as well as patients with intermediate to high-risk primary membranous nephropathy
Trial Details
NCT Number NCT06690359
Lead Sponsor Beijing Immunochina Medical Science & Technology Co., Ltd.
Conditions IgA Nephropathy, Membranous Nephropathy
Enrollment 12 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov